Moderna

Moderna's shares soared after the company said its potential vaccine to prevent Covid-19 produced a "robust" immune response in all 45 patients in its early stage human trial, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine.Moderna's stock rose more than 16% in after-hours trading on the news. All…

Moderna Inc (NASDAQ: MRN) shares are surging above the $70 level for the first time since late May following sell-side commentary on its coronavirus vaccine program. The Moderna Analyst: Jefferies analyst Michael Yee initiated coverage of Moderna with a Buy rating and $90 price target. The Moderna Thesis: There is good probability the vaccine will work…

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/moderna-stock-jumps-as-analyst-expects-the-fda-to-approve-its-covid-19-vaccine-51594653061 July 13, 2020 11:11 am ET Order Reprints Print Article Shares of Moderna are up 239% so far this year, and the biotech company, which has no approved drugs, has a…

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New YorkGENEVA (Reuters) - AstraZeneca's experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday.The British drugmaker has…

Moderna said Thursday that starting in 2021, it could manufacture "possibly up to 1 billion doses per year" of its experimental coronavirus vaccine with the help of a contract manufacturer.Yes, but: 1 billion vaccine doses may sound like a lot, but government and public health leaders would inevitably still have to make hard choices about…